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Introduction.The renin granulation of kidney arterioles is enhanced in diabetes despite the fact that the level of angiotensin II in the
diabetic kidney is elevated. Therefore, the number of angiotensin II AT1-A and AT1-B receptors in afferent and efferent arteriole’s
renin-positive and renin-negative smooth muscle cells (SMC) was estimated. Method. Immunohistochemistry at the electron
microscopic level was combined with 3D stereological sampling techniques. Results. In diabetes the enhanced downregulation
of AT1-B receptors in the renin-positive than in the renin-negative SMCs in both arterioles was resulted: the significant difference
in the number of AT1 (AT1-A +AT1-B) receptors between the two types of SMCs in the normal rats was further increased in diabetes
and in contrast with the significant difference observed between the afferent and efferent arterioles in the normal animals, there
was no such difference in diabetes. Conclusions. The enhanced downregulation of the AT1-B receptors in the renin-negative SMCs
in the efferent arterioles demonstrates that the regulation of the glomerular filtration rate by the pre- and postglomerular arterioles
is changed in diabetes.The enhanced downregulation of the AT1-B receptors in the renin-positive SMCs in the arterioles may result
in an enhanced level of renin granulation in the arterioles.
1. Introduction
The juxtaglomerular apparatus (JGA) is a morphological
complex which regulates the glomerular filtration rate. All of
its elements are controlled by the renin angiotensin system
(RAS) via the angiotensin II receptors. The activity of the
RAS on JGA is expressed in the number of angiotensin II
receptors, such as the AT1-A, AT1-B and AT2 receptors. The
effect of the angiotensin II on the arteriolar tone is related
to the AT1-A and AT1-B, receptors [1]. In normal rat kidney
arterioles, the number ofAT1-A receptors is downregulated in
the renin-positive smooth muscle cells (SMCs) as compared
with the renin-negative SMCs [2]. There is a significant
difference between the afferent and efferent arterioles in the
number of AT1-B receptors, which are upregulated on the
SMC surface on the efferent arterioles [2].
Via the negative feedback, angiotensin II inhibits the
transdifferentiation between the renin-negative SMC and
renin-positive SMC. In response to treatment with an
angiotensin II blocker, such as candesartan, the extent of
renin granulation of the afferent arterioles is increased [3,
4]. The level of angiotensin II in the diabetic kidney is
significantly higher than the normal level, while the level
of renin granulation of the afferent arterioles is increased
[5, 6]. Thus, the negative feedback from renin synthesis
should be downregulated (through an unknownmechanism)
because the extent of renin granulation of the afferent
arterioles is higher than normal [7]. Our theory suggests
that the number of AT1 receptors is downregulated not only
in the SMC, but also to an extreme degree in the renin-
granulated SMCs in diabetes.We have estimated the numbers
of angiotensin II AT1-A and AT1-B receptors on the surface of
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renin-positive and renin-negative SMCs. Since the arteriolar
tone is controlled by angiotensin II via the AT1 receptors
[1], the AT1 receptor subtypes in diabetic rat kidneys were
estimated on the afferent and efferent arterioles separately.
2. Materials and Method
2.1. Animals with STZ-Induced Diabetes. Streptozotocin
(Sigma, USA) was administered intraperitoneally in dose of
60mg/kg to adult male Wistar rats (300–400 g; 𝑛 = 5).
After 48 h, the blood sugar level was measured; those animals
where the blood sugar level exceeded 18mMwere regarded as
diabetic. The blood sugar level and the weight of the animals
were followed over a period of 10 weeks, after which the rats
were killed.
2.2. The Measurement of Angiotensin II Level. The sample
collections (blood: phlebotomy from Vena cava posterior-
vacutainer EDTA tube; kidney: after laparotomy kidneys
were excised, purified from adipose tissue) at the end of
the streptozotocin treatment were carried out. It was used
the Uscn Life Science Inc. ELISA kit (Cat.no.US-E90005Ra)
to determine the level of angiotensin II from bloods and
kidney tissue samples, which has high sensitivity for detection
of Angiotensin II. The preparation of tissue and blood was
strictly followed in accordance with the user manual of the
kit.
2.3. Immunohistochemistry. For immunohistochemical pur-
poses, the same protocol was performed as described earlier
[2]. Sections placed on glass slides were washed in PBS
(pH = 7.4) for 10min and then incubated in normal goat
serum 1 : 100 (EMS, USA) in PBS (pH = 7.4) for 20min. The
primary antibody against the AT1-A or AT1-B receptor of
angiotensin II (rabbit polyclonal, Advance Targeting Systems,
San Diego, USA) was diluted 1 : 50 in PBS (pH = 7.4) and
left overnight at 4∘C in a wetting chamber. The sections were
subsequently washed three times for 5min each in PBS (pH=
7.4). 0.8 nm gold-conjugated goat-anti-rabbit IgG (Aurion
Immunogold, EMS, USA) was diluted 1 : 100 in PBS (pH =
7.4), allowed to stand for 2 h, and then washed three times
for 5min each in PBS (pH = 7.4). The sections were fixed
with 3% glutaraldehyde in PBS (pH = 7.4) and washed with
distilledwater for 5min, followed by silver enhancementwith
Danscher solution (Aurion R-gent SE-EM, EMS, USA) for
75min at 25∘C, resulting in a particle size around 30 nm.
Finally, the sections were washed three times for 5min each
with distilled water.
2.4. Embedding and Sectioning. The immunostained serial
sections placed on glass slides were dehydrated with ordinary
series of ethanol and acetone and infiltrated for 10min with
epoxy resin (TAAB 812). The sections were then capped with
plastic capsules filled with clean resin.The semithin (0.4𝜇m)
and thin (70±5 nm; mean ± SD) sections were prepared with
an Ultracut S (Leica) ultramicrotome.The thin sections were
stained with uranyl acetate and lead citrate.
Stereology. For sampling, the same protocol was applied as
previously [8]. An afferent arteriole was defined as a pre-
glomerular arteriole from the glomerulus to the first branch-
ing. An efferent arteriole was defined as a postglomerular
arteriole from the glomerulus to the capillary. Each arteriole
was followed on series of semithin sections, and profiles
appearing from the same arteriole were identified [9, 10].The
TEM micrographs were prepared with an Analysis software
3.1 module (Soft Image System GmbH,Mu¨nster) on a Philips
CM10 electron microscope (FEI, Eindhoven) equipped with
a MegaView II camera. The immunohistochemical signals
of AT1-A or AT1-B receptor molecules were counted on
the surface of arteriolar SMCs, renin-granulated cells, and
endothelial cells of afferent and efferent arterioles. More
details are to found in recent articles by Razga andNyengaard
[2, 11].
2.5. Statistics. For the comparison of differences between the
two groups, Student’s 𝑡-test was applied.
3. Results
3.1. Diabetic Animals. The STZ treatment was successful:
the blood sugar level of the animals had increased 3-fold
significantly by the end of 10 weeks (Table 1).
3.2. The Angiotensin II Level in Plasma and Kidney. There
were no significant difference between the control and dia-
betic in the angiotensin level of plasma or kidney after the
10-week STZ treatment (Table 2).
3.3. Regulation of AT1-A and AT1-B Receptors. The downreg-
ulation of the AT1-A receptors in the endothelial cells of the
arterioles differed from that of the AT1-B receptors (Figure 1).
The AT1-A receptors were downregulated equally in the
renin-positive (Figures 4 and 5) and renin-negative SMCs
(Figure 2(a)), while in diabetes the significant difference in
the number of AT1-A receptors between the renin-positive
and renin-negative SMCs was unchanged (Table 3).The AT1-
B receptors were downregulated more in the renin-positive
than in renin-negative SMCs in both types of arterioles
(Figure 2(b); Table 3). The significant difference in the num-
ber of AT1 (AT1-A + AT1-B) receptors between the two types
of SMCs in the normal rats was further increased in diabetes
(Table 3). The AT1-B receptors were downregulated more in
the efferent than in the afferent arterioles (Figures 3(a) and
3(b)); in contrast with the significant difference observed
between the afferent and efferent arterioles in the normal
animals, there was no such difference in diabetes (Table 4).
4. Discussion
Our results demonstrated that AT1-A or AT1-B receptors of
angiotensin II downregulated heterogeneously in different
cells and arterioles, while the angiotensin II level in plasma
and kidney does not show any significant differences after 10
weeks of STZ treatment. The angiotensin II level in kidney
increased by STZ-induced diabetes 12–20 weeks [12]. In our
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Table 1: Changes in blood sugar level and weight following the STZ diabetic protocol.
Animal weight (g) Blood sugar level (mM/L)
Mean Mean SD
Control Start 𝑛 = 4 354 6.7 0.43
10 weeks 𝑛 = 4 457 5.53 0.86
Diabetic Start 𝑛 = 5 360 6.25 0.49
10 weeks 𝑛 = 5 318 20.25 9.68
Table 2: Angiotensin II level in plasma and kidney (pg/mL).
𝑛
Control Diabetes
Mean (CV) Mean (CV)
Angiotensin II
plasma
level (pg/mL)
3 270 (0.56) 246 (0.29) NS
Angiotensin II
kidney
level (pg/mL)
3 666 (0.02) 668 (0.04) NS
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Figure 1: Downregulation of the AT1 receptor subtypes in the
endothelia in the arterioles.
project the evidence that the proceedings of angiotensin II
receptors downregulation are independent from angiotensin
II level was provided.
4.1. Specificity of Antibodies Labeled AT1-A and AT1-B Recep-
tors. The selectivity of primary antibody against the AT1-A
or AT1-B receptors of angiotensin II was guaranteed in earlier
demonstration of estimating the AT1-A or AT1-B receptor of
angiotensin II in afferent and efferent arterioles of kidney in
normal rat [2]. In this study the results from the earlier job
using the nonselective primary antibody against the subtypes
of AT1 receptors (rabbit IgG; Santa Cruz Biotechnology,
USA) by using the two primary antibodies selective to AT1-
A or AT1-B receptors (rabbit polyclonal, Advance Targeting
Systems, San Diego, USA) [2, 11] were reproduced.
4.2. The Effect of Insulin on the Regulation of the AT1
Receptors. Insulin causes an upregulation of the AT1 receptor
gene expression in the vascular SMCs in cell cultures. The
AT1 receptor upregulation results in an enhanced func-
tional response of the vascular SMCs on stimulation with
angiotensin II [13, 14]. In our experiment, 10 weeks after the
onset of STZ-induced diabetes, the AT1 receptors (AT1-A
and AT1-B) were downregulated in the afferent and efferent
arterioles; this downregulation was extreme and hetero-
geneous. In normal cells, the number of AT1-A receptors
on surfaces of renin-positive and renin-negative SMCs was
earlier reported to be decreased by 27–40% [2, 11], while
the downregulation in our diabetic rats in the different cells
of the JGA range between 61 and 82% (Figures 1–3). This
level of downregulation in diabetes is extreme compared
to the normal level. It is heterogeneous because the AT1-A
and AT1-B receptors are downregulated to different extents
in the various cell types in the JGA. Differences were also
foundbetween the afferent and efferent arteriolar SMCs in the
downregulation of the AT1-B receptor. One possible reason
for the significant and heterogeneous downregulation of the
AT1 receptors on the cells of the arterioles is the insulin level
reduction caused by STZ treatment.
4.3. Regulation of AT1 Receptor Subtypes in the Afferent
and Efferent Arterioles in Diabetic Kidneys. Angiotensin II
regulates both the afferent and the efferent arteriolar tone
via the AT1 receptors [1, 15]. The physiological data indicate
that angiotensin II exerts a stronger contractility effect on
the postglomerular than on the preglomerular arterioles in
normal animals [16].Themechanisms of these heterogeneous
contractile effects were clarified by our earlier work, as the
angiotensin II AT1 receptor is upregulated in the efferent
arterioles as compared with the afferent arterioles, and this
upregulation is specific for the AT1-B receptor [2, 11]. The
angiotensin II level in the kidney is elevated in STZ-induced
diabetes [5, 6, 12]. Our results have demonstrated that the
AT1-A and AT1-B receptors are downregulated in the afferent
and efferent arterioles in STZ-induced diabetic kidneys. This
downregulation of the AT1-A and AT1-B receptors could
compensate for the contractile effect on the arteriolar SMCs
by a high level of angiotensin II in diabetic kidneys.
The efferent arteriolar contraction brought about by
angiotensin II results in the opposite effect on the GFR to that
caused by afferent arteriolar contraction [17]. In diabetes, the
downregulation of the AT1 receptors on the efferent arterioles
was enhanced in the AT1-B subtype, which changed to equal
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Table 3:The relative numbers of angiotensin II AT1 receptor subtypes in the renin-negative and renin-positive SMCs in STZ-induced diabetic
and normal rat kidney arterioles. The normal state in the number of AT1-B receptors between the renin-negative and renin-positive SMCs is
changed to significantly different in diabetes, because of the enhanced downregulation of the AT1-B receptors in renin-positive SMCs.
𝑛
Renin-positive
SMCs Renin-negativeSMCs Difference 𝑃
Mean (CV)
Angiotensin II AT1-A receptors
in afferent arterioles cells surface
(signals/um3)
Normal 4 0.133 (0.42) 0.215 (0.18) 38% 0.026
Angiotensin II AT1-B receptors
in afferent arterioles cells surface
(signals/um3)
Normal 4 0.203 (0.34) 0.176 (0.11) 13.3% NS
Angiotensin II AT1-A receptors
in afferent arterioles cells surface
(signals/um3)
Diabetic 5 0.0345 (0.52) 0.058 (0.31) 41% 0.035
Angiotensin II AT1-B receptors
in afferent arterioles cells surface
(signals/um3)
Diabetic 5 0.033 (0.45) 0.055 (0.16) 40% 0.0096
Angiotensin II AT1-(A + B)
receptors in afferent arterioles
cells surface (signals/um3)
Normal 4 0.156 (0.27) 0.216 (0.18) 27.8% 0.043
Angiotensin II AT1-(A + B)
receptors in afferent arterioles
cells surface (signals/um3)
Diabetic 5 0.035 (0.30) 0.057 (0.38) 37.8% 0.041
Table 4:The relative numbers of angiotensin II AT1 receptor subtypes in SMCs in the afferent and efferent arterioles in STZ-induced diabetic
and normal rat kidneys. The normal state in the number of AT1-B receptors between the afferent and efferent arteriole is changed to equal in
diabetes, because of enhanced downregulation of AT1-B receptor in the efferent arteriole.
𝑛
Afferent
arterioles
Efferent
arterioles Difference
𝑃
Mean (CV)
Angiotensin II AT1-A receptors
in SMCs surface (signals/um3) Normal 4 0.215 (0.18) 0.283 (0.19) 24% NS
Angiotensin II AT1-B receptors
in SMCs surface (signals/um3) Normal 4 0.176 (0.11) 0.312 (0.38) 44% 0.034
Angiotensin II AT1-A receptors
in SMCs surface (signals/um3) Diabetic 5 0.062 (0.73) 0.043 (0.9) 30% NS
Angiotensin II AT1-B receptors
in SMCs surface (signals/um3) Diabetic 5 0.053 (0.19) 0.064 (0.34) 17% NS
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Figure 2: The angiotensin II AT1 receptors are downregulated in both renin-positive and renin-negative SMCs in arterioles.
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Figure 3: The angiotensin II AT1-B receptor is downregulated in the SMCs of the afferent and efferent arterioles.
Figure 4: Immunohistochemical staining of AT1-A receptors on
renin-positive SMCs of afferent arteriole in diabetes. There is less
signal on cell surface than in normal. The original magnification of
TEMmicrograph was 13500x (1972 × 1828 pixel).
the significant difference in the total number of the AT1-
B subtypes between the afferent and efferent arterioles of
normal kidneys. This heterogeneous downregulation of the
AT1-B receptor might decrease the efferent arteriolar effect of
angiotensin II on the GFR.
4.4. Regulation of Renin Synthesis in STZ-Induced Diabetes.
Renin synthesis is enhanced by angiotensin II via the AT1
receptors in the collecting ducts [16, 18]. An opposite effect
of angiotensin II occurs in the afferent arterioles, where
angiotensin II inhibits the transdifferentiation between the
renin-negative SMCs and the renin-positive SMCs via the
AT1 receptors. The receptor that mainly regulates this trans-
differentiation is the AT1-A receptor [2].
Figure 5: Immunohistochemical staining of AT1-A receptors on
renin-positive SMCs of afferent arteriole in normal rats. There is
more signal on cell surface than in diabetes. The original magnifi-
cation of TEMmicrograph was 13500x (2152 × 1844 pixel).
In STZ-induced diabetic rats, the angiotensin II level in
the kidney is higher than in normal rats [5, 6, 12]. Thus, the
extent of renin synthesis in the collecting ducts should be
increased and the level of renin granulation of the afferent
arterioles should be decreased. The former holds true for
diabetes: the main source of renin is the collecting duct
[5, 6, 16], but the level of renin granulation in the afferent
arterioles is higher in diabetes [7]. Our results have revealed
that the AT1-A and AT1-B receptors were downregulated in
both the renin-positive and renin-negative SMC surfaces.
As concerns the AT1-A receptors the difference between the
renin-positive and renin-negative SMCs is the same as in
normal rats.However, theAT1-B receptors are downregulated
more in the renin-positive than in the renin-negative SMC.
The total number of AT1 (AT1-A + AT1-B) receptors is
reduced in diabetes. One possible reason for the high level
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of renin granulation of the afferent arterioles with the high
level of angiotensin II in diabetes might be the enhanced
downregulation of the AT1-B receptors of the SMC.
5. Conclusions
In diabetes, the activity of the RAS is downregulated less in
the endothelial cells than in the SMC. The enhanced down-
regulation ofAT1-B in the renin-negative SMCs of the efferent
arterioles demonstrates that the regulation of the glomerular
filtration rate by the pre- and postglomerular arterioles is
changed in diabetes. The enhanced downregulation of the
AT1-B receptors in the renin-positive SMCs of the arterioles
may result in an enhanced extent of renin granulation of the
arterioles in response to high levels of angiotensin II in the
diabetic kidney.
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